Literature DB >> 12951041

Immunization with a dicistronic plasmid expressing a truncated form of bovine herpesvirus-1 glycoprotein D and the amino-terminal subunit of glycoprotein B results in reduced gB-specific immune responses.

Sharmila Manoj1, Lorne A Babiuk, Sylvia van Drunen Littel-van den Hurk.   

Abstract

As an approach to create a divalent DNA vaccine, a truncated secreted version of bovine herpesvirus-1 (BHV-1) glycoprotein D (tgD) and the amino-terminal subunit of glycoprotein B (gBb) were expressed from a dicistronic plasmid, designated pSLIAtgD-IRES-gBb. Intradermal immunization of mice with pSLIAtgD-IRES-gBb or a mixture of plasmids encoding tgD (pSLIAtgD) and gBb (pSLIAgBb) by needle injection or gene gun elicited strong tgD-specific immune responses. However, a significant reduction in gBb-specific immune responses was observed upon immunization of mice with pSLIAtgD-IRES-gBb or a mixture of pSLIAtgD and pSLIAgBb in comparison to immunization with pSLIAgBb alone. This reduction in gBb-specific immune responses induced by pSLIAtgD-IRES-gBb was due to production of low amounts of gBb from pSLIAtgD-IRES-gBb, inefficient processing and transport of gBb, and possibly competition for antigen-presenting cells by tgD and gBb. These results indicate that, although divalent plasmids may be used to express different antigens, the efficacy of vaccination with such plasmids may be influenced by the plasmid design and the characteristics of the expressed antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12951041     DOI: 10.1016/s0042-6822(03)00325-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Immunogenicity of a bovine herpesvirus 1 glycoprotein D DNA vaccine complexed with bovine neutrophil beta-defensin 3.

Authors:  Sarah Mackenzie-Dyck; Laura Latimer; Ethel Atanley; Jennifer Kovacs-Nolan; Sam Attah-Poku; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

2.  Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8⁺ T cell responses and protective immunity.

Authors:  Vinicius C Santana; Mariana O Diniz; Francisco A M O Cariri; Armando M Ventura; Edécio Cunha-Neto; Rafael R Almeida; Marco A Campos; Graciela K Lima; Luís C S Ferreira
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

3.  A DNA Vaccine Formulated with Chemical Adjuvant Provides Partial Protection against Bovine Herpes Virus Infection in Cattle.

Authors:  Valeria Quattrocchi; Ivana Soria; Cecilia Ana Langellotti; Victoria Gnazzo; Mariela Gammella; Dadin P Moore; Patricia I Zamorano
Journal:  Front Immunol       Date:  2017-01-25       Impact factor: 7.561

4.  Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with a chlamydial component.

Authors:  Chantal Brunner; Theo Kanellos; Marina L Meli; David J Sutton; Ricarda Gisler; Maria Alice Gomes-Keller; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vaccine       Date:  2005-11-15       Impact factor: 3.641

5.  Field Evaluation of Commercial Vaccines against Infectious Bovine Rhinotracheitis (Ibr) Virus Using Different Immunization Protocols.

Authors:  Laureana De Brun; Mauro Leites; Agustín Furtado; Fabricio Campos; Paulo Roehe; Rodrigo Puentes
Journal:  Vaccines (Basel)       Date:  2021-04-20

6.  Clinical protection of goats against CpHV-1 induced genital disease with a BoHV-4-based vector expressing CpHV-1 gD.

Authors:  Gaetano Donofrio; Valentina Franceschi; Angela Lovero; Antonio Capocefalo; Michele Camero; Michele Losurdo; Sandro Cavirani; Mariarosaria Marinaro; Erika Grandolfo; Canio Buonavoglia; Maria Tempesta
Journal:  PLoS One       Date:  2013-01-03       Impact factor: 3.240

7.  Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge.

Authors:  Diletta Magini; Cinzia Giovani; Simona Mangiavacchi; Silvia Maccari; Raffaella Cecchi; Jeffrey B Ulmer; Ennio De Gregorio; Andrew J Geall; Michela Brazzoli; Sylvie Bertholet
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.